Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin

Journal of Hypertension

Volumn 20, Issue 12, 2002, Pages 2513-2517

  West, Malcolm J ^a   White, Harvey D ^b   Simes, R John ^c   Kirby, Adrienne ^c   Watson, John D ^d   Anderson, Neil E ^e   Hankey, Graeme J ^f   Wonders, Susan ^c   Hunt, David ^g   Tonkin, Andrew M ^h  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GREEN LANE HOSPITAL   (New Zealand)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f ROYAL PERTH HOSPITAL   (Australia)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

Coronary heart disease; Non haemorrhagic stroke; Pravastatin; Risk factors; Transient ischaemic attack

Indexed keywords

CHOLESTEROL; CREATININE; PRAVASTATIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK;

EID: 0036910657     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200212000-00032     Document Type: Article

References (21)

1. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischaemic stroke. Circulation 2001; 103:163-182.
2. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998; 352:1801-1807.
3. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346:1647-1653.
4. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the phospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997.
5. Bushnell CD, Gordstein LB. Ischaemic stroke; recognizing risks unique to women. Womens Health Primary Care 1999; 2:788-804.
6. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum choresterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904-910.
7. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995; 155:50-55.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
9. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622.
10. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: A meta-analysis of randomized, controlled trials. Ann Intern Med 1998; 128:89-95.
11. Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence following myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. Circulation 1999; 99:216-223.
12. Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, Shepherd J. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103:387-392.
13. MRC/BHF Heart Protection Study of choresterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
14. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JDG, Hunt D, et al. Impact of pravastatin therapy on the risk of stroke: Results from the LIPID study. N Engl J Med 2000; 343:317-326.
15. The LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76: 474-479.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
18. Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischaemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990; 21:848-853.
19. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002; 359:1379-1387.
20. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein; the Cholesterol And Recurrent Events (CARE) investigators. Circulation 1999; 100: 230-235.
21. MacMahon S. Blood pressure and the risks of cardiovascular disease. In: Swales JD, editor: Textbook of Hypertension. Oxford: Blackwell Scientific Publications; 1994. pp. 46-57.